Breaking News: Terns Upsizes Public Offering to $150.15 Million – Find Out the Details!

newsmaker03 mins

Terns Pharmaceuticals, Inc. Announces Pricing of Public Offering Introduction Terns Pharmaceuticals, Inc. has recently made headlines with the announcement of the pricing of its upsized underwritten public offering. The clinical-stage biopharmaceutical company is focused on developing small-molecule product candidates to tackle serious diseases, including oncology and obesity. This latest development is set to have a…

Read More

Attention VICOR Shareholders: Don’t Miss Out on Your Chance to Seek Justice! Former Louisiana Attorney General Reminds Investors of Upcoming Deadline in Class Action Lawsuit

SpotlightSource03 mins

Are You Ready to Take Action? Act Fast or Miss Out! Don’t Let Opportunity Slip Away Hey there, savvy investors! Have you heard about the latest opportunity to potentially recoup losses in the stock market? If not, don’t worry – we’ve got you covered. Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney…

Read More

Unlocking the Latest Bitcoin Buzz: Glassnode’s Report on Hashrate Hikes, ETF Exodus, and Investor Involvement

marketinsider03 mins

Hey There, Crypto Enthusiasts! Let’s Talk Bitcoin Hashrate and Miner Resilience So, I was just scrolling through Glassnode’s latest report and boy, oh boy, did it drop some interesting insights! It turns out that despite falling revenues for miners, Bitcoin’s hashrate is on the rise. Yup, you heard that right! Miners are persisting like champs…

Read More

Unleashing the Future: Apple’s Spectacular Launch of the iPhone 16 Lineup, AirPods, and More!

InformedNow05 mins

Tech Giant Apple Introduces the New iPhone 16 Series Revolutionizing the Smartphone Industry On Monday, tech giant Apple unveiled its latest innovation – the iPhone 16 series. This new line of smartphones is set to revolutionize the industry with groundbreaking features such as artificial intelligence integration, larger display sizes, a new camera control button, and…

Read More

Breaking News: Innovent Presents Exciting Phase 1 Clinical Data for IBI363, a Revolutionary PD-1/IL-2 Bispecific Antibody Fusion Protein, in Advanced Non-Small Cell Lung Cancer at 2024 WCLC!

marketnews05 mins

Welcome to the World of Biopharmaceuticals! An Exciting Announcement from Innovent Biologics SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) has recently made waves in the biopharmaceutical world with the presentation of Phase 1 clinical data for their groundbreaking IBI363 drug. IBI363 is a first-in-class PD-1/IL-2α-bias bispecific…

Read More